In the best-case scenario, treatment with HDAC inhibitors induces growth arrest or cell death of cancer cells; however, under unfavorable conditions, these agents can impede the effect of other anticancer therapeutics or may even promote tumor growth. The gene discussed is HDAC9; the disease is neoplasm.